Antibody Titer (levels) can depend on several things:

1. What type of antibody is being measured and at what point in time you are measuring for this specific antibody (there are multiple antibodies that show up at different times after vaccination). See photo for more details.

- The **IgG** antibody is an indicator of longer lasting immunity.



2. If the person being vaccinated was previously infected with COVID-19.
3. The status of the person's immune system and their age.
4. Differences in antibody amounts after the first vs. second shot.

EXAMPLE: PFIZER VACCINE[1]

Average IgG levels in patients 65-85 who got 30micrograms* of Pfizer vaccine after **DOSE 1 for patients 18-55 years of age**:	
Day 1-21 after dose 1	853 (U/ml)
Day 21-28 after dose 1	23516 (U/ml)
Day 28-35 after dose 1	13940 (U/ml)
Average IgG levels in patients 65-85 who got 30micrograms* of Pfizer vaccine after **DOSE 2 for patients 18-55 years of age**:	
Day 1-21 after dose 2	1265 (U/ml)
Day 21-28 after dose 2	9136 (U/ml)
Day 28-35 after dose 2	8147 (U/ml)

**Note: 30 micrograms is the current dose or amount that is being given and is available on the market. (U/ml = units per milliliter)*

Average IgG levels in patients 65-85 who got 30micrograms* of Pfizer vaccine after

DOSE 1 for patients 65-85 years of age:	
Day 1-21 after dose 1	86 (U/ml)
Day 21-28 after dose 1	6580 (U/ml)
Day 28-35 after dose 1	4798 (U/ml)
Average IgG levels in patients 65-85 who got 30micrograms* of Pfizer vaccine after **DOSE 2 for patients 65-85 years of age**:	
Day 1-21 after dose 2	329 (U/ml)
Day 21-28 after dose 2	7985 (U/ml)
Day 28-35 after dose 2	6014 (U/ml)

**Note: 30 micrograms is the current dose or amount that is being given and is available on the market. (U/ml = units per milliliter)*

References

1. Walsh, E. E., Frenck, R. W., Jr, Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P. Y., Türeci, Ö., Tompkins, K. R., Lyke, K. E., … Gruber, W. C. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. *The New England journal of medicine*, *383*(25), 2439–2450. https://doi.org/10.1056/NEJMoa2027906